+357 96 030922
info@marketpublishers.com

Malignant Melanoma: Update Bulletin [Jan 2016]

https://marketpublishers.com/r/M6EC9DB3295EN.html
Date: December 2015
Pages: 0
Price: US$ 995.00 (Single User License)
ID: M6EC9DB3295EN

Abstracts

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo's (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy's (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA's approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma's binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen's newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.

Key Questions Answered in this Update Bulletin:

Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?

To what extent will Keytruda be used as a first-line therapy for advanced melanoma?

Will Opdivo plus Yervoy's superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?

What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?

How significantly will the need for patient monitoring impact Yervoy's uptake in stage III melanoma?

+357 96 030922
info@marketpublishers.com

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

Gain new KOL insights on the latest events happening in Malignant melanoma (MM): Opdivo's (nivolumab; Bristol-Myers Squibb) label expansion to allow its use both as a monotherapy for the first-line treatment of BRAF V600 wild-type advanced melanoma, and in combination with Yervoy (ipilimumab; Bristol-Myers Squibb), also for treating BRAF V600 wild-type advanced melanoma; Yervoy's (ipilimumab; Bristol-Myers Squibb) use as an adjunctive therapy for stage III melanoma; FDA's approval of Keytruda (pembrolizumab; Merck & Co.) for the first-line treatment of advanced melanoma; Views on the role of Array BioPharma's binimetinib as a therapy for NRAS-mutant melanoma, and the prospects for Amgen's newly-approved oncolytic immunotherapy Imlygic (talimogene laherparepvec), are also summarised.

Key Questions Answered in this Update Bulletin:

Will Opdivo monotherapy use increase significantly following BRAF V600 wild-type label expansion?

To what extent will Keytruda be used as a first-line therapy for advanced melanoma?

Will Opdivo plus Yervoy's superior efficacy be sufficient to secure a role for the combination in the BRAF V600 wild-type setting?

What do KOLs think about Imlygic plus checkpoint inhibitors, to the future success of this oncolytic immunotherapy?

How significantly will the need for patient monitoring impact Yervoy's uptake in stage III melanoma?

How successful do KOLs think that binimetinib will be for treating advanced NRAS-mutant melanoma?

+357 96 030922
info@marketpublishers.com

Update Bulletins include expert insight and analysis based on FirstWord analyst re-engagement with the KOLs after major events such as product approvals, key data releases and major conferences to deliver the most valuable insights with each update.

+357 96 030922
info@marketpublishers.com

I would like to order

Product name: Malignant Melanoma: Update Bulletin [Jan 2016]

Product link: https://marketpublishers.com/r/M6EC9DB3295EN.html

Price: US$ 995.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:
info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/M6EC9DB3295EN.html